# 2017 FULL YEAR RESULTS

0

# **GROWTH CONTINUATION**



# DISCLAIMER


This presentation contains forward-looking statements concerning the financial condition, results of operations and businesses of the Group. Although the Group believes that the expectations reflected in such forward-looking statements are reasonable, these statements are not guarantees of future performance and are subject to a number of risks and uncertainties and actual results, performance and events could differ materially from those currently being anticipated, expressed or implied in such forward-looking statements.

Factors which may cause future outcomes to differ from those foreseen in forward-looking statements include, but are not limited to, those identified under "Principal Risks and Uncertainties" of the Group's Annual Report.

The forward-looking statements contained in this presentation speak only as of the date of preparation of this presentation and the Group therefore cautions against placing undue reliance on any forward-looking statements. Nothing in this presentation should be construed as a profit forecast. Except as required by any applicable law or regulation, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this presentation to reflect any change in the Group's expectations or any change in events, conditions or circumstances on which any such statement is based.

This presentation does not constitute or form part of any offer or invitation to purchase any securities of any person nor any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any such securities.

# 2017: GROWTH ACCELERATION PLAN COMPLETED



The goal is simple but demanding: progressively to return every part of our business to growth, and simultaneously to build the capabilities and platforms needed for future scale and consistent performance.

**Informa Annual Report** 2014

STEPHEN A. CARTER GROUP CHIEF EXECUTIVE

# 2017 PERFORMANCE & DELIVERY

# 2017: GROWTH ACCELERATION PLAN COMPLETED

GROWTH	Fourth year of growth in Revenue, Adjusted EPS, Cashflow & Dividends
DELIVERY	Operational capability and platform for future growth and scale through GAP
INTEGRATE	Effective integration of Penton Information Services delivered ahead of plan
FOCUS	Continued portfolio management through sale of Euroforum and Garland
EXPAND	Additions of YPI in Global Exhibitions and Dove Medical in Academic Publishing
SCALE	Recommended offer for UBM plc to create leading B2B Information Services Group

# A YEAR OF PERFORMANCE AND DELIVERY

# **2017: PERFORMANCE AND DELIVERY**





# **GROWTH ACCELERATION PLAN: KEY INITIATIVES**



Build and buy a scale B2B events business in the **Global Exhibitions** Division

- 2 Repair and return to growth the **Business Intelligence** Division
- 3 Simplify, focus and grow the **Knowledge & Networking** Division
  - Build scale and management capability in the US market
- 5 Invest in platforms and capabilities for future scale and growth in all 5 divisions

GARETH WRIGHT GROUP FINANCE DIRECTOR

# 2017 FINANCIAL PERFORMANCE & DELIVERY

# **2017 FULL YEAR RESULTS**

₼ 30.7%

Higher Reported Revenue, including Penton and YPI

+30.7% to £1,757.6m (2016: £1,344.8m)

+3.4%

Growth

# +31.3%

Increased Adjusted Operating Profit

+31.3% to £545.5m (2016: £415.6m)

# +9.5%

**Growth in Adjusted Diluted EPS** +9.5% to 46.1p (2016: 42.1p)

**2.5x** 

**Robust Balance Sheet** 

Net debt/EBITDA 2.5 times (2016: 2.6 times)

# **6.0%**

**Enhanced Dividend Per Share** up 6.0% to 20.45p (2016: 19.30p)

# +31.1%

Strong Free Cash Flow


+31.1% to £400.9m (2016: £305.7m)

CONTINUED OPERATIONAL PERFORMANCE AND FINANCIAL DELIVERY

**Increasing Underlying Revenue** 

# **REVENUE GROWTH MIX**

#### 2017 REVENUE GROWTH (%)



# **EFFECTIVE INTEGRATION OF PENTON INFORMATION SERVICES**

COMBINE	Effective integration into Informa, led by Patrick Martell (Business Intelligence), Charlie McCurdy (Global Exhibitions) and Andrew Mullins (Knowledge & Networking)
SCALE	On track to deliver at least \$22.5m of gross synergies in 2018 through removal of duplicate cost, management and systems overlap and procurement benefits
SPECIALISATION	Franchises left intact within Informa to reap benefits of industry specialisation
REVENUE	Significant revenue opportunities through cross-marketing, internationalisation etc
ENGAGE	Launch of specialist Data & Marketing Solutions business Informa Engage
EXPAND	Addition of Penton builds on US market position established through Virgo Publishing and Hanley Wood Exhibitions

## **OPERATING AND REPORTING AS A SINGLE BUSINESS**

## PENTON COST SYNERGIES ON TRACK



\*Annual recurring pre-tax savings. Net savings are after \$4m investment in benefits harmonisation

# SIGNIFICANT INCREMENTAL REVENUE OPPORTUNITIES

### 6-STEP REVENUE GROWTH PLAN: PENTON INFORMATION SERVICES

1	Cross-Marketing	From Ingredients to Finished Goods: leveraging relationships across the value chain: strong growth in Vitafoods Europe and doubling of Vitafoods Asia
2	Internationalisation	Launch of SupplySide China in Guangzhou in 2018
3	Data & Marketing	More than £10m of revenue from non-events activities at GHNN
4	Digitisation	Launch of Markit Makr product for Health & Nutrition in 2018
5	Sponsorship	Introduction of multi-event sponsorship products across different verticals eg Major financial services sponsor
6	Customer Value	Rollout of Customer Value Programme across portfolio with launch at Vitafoods Europe in 2018

# ALL FOUR DIVISIONS IN GROWTH


		2017		2016	I	Ictual	Underlying
		£m		£m		%	%
Revenue							
Global Exhibitions		560.4		321.1		74.5	7.6
Business Intelligence		384.2		302.4		27.1	2.2
Academic Publishing	1. 1. 1. 1. 1. 1.	530.0	r i	490.4		8.1	2.0
Knowledge & Networking		283.0	Sec. 2	230.9		22.6	0.1
Group		1,757.6		1,344.8		30.7	3.4
Adjusted Operating Profit							
Global Exhibitions		201.4		119.5		68.5	6.5
Business Intelligence		92.2		70.5	-	30.8	6.2
Academic Publishing		208.0		187.2		11.1	0.7
Knowledge & Networking		43.9		38.4		14.3	(13.3)
Group		545.5		415.6		31.3	2.3
Operating Margins		%		%			
Global Exhibitions		35.9		37.2			
Business Intelligence		24.0		23.3			
Academic Publishing		39.2		38.2			
Knowledge & Networking		15.5		16.6			
Group		31.0		30.9	1.		

# GROWTH IN REVENUE, ADJUSTED PROFIT AND EARNINGS

	2017 £m	2016 £m
Revenue	1,757.6	1,344.8
Adjusted Operating Profit	545.5	415.6
Adjusted Operating Margin	31.0	30.9
Net interest	(59.1)	(39.6)
Adjusted profit before tax	486.4	376.0
Adjusting items	(217.6)	(197.9)
Reported Profit before tax	268.8	178.1
Adjusted tax charge	(103.1)	(67.8)
Effective tax rate	21.2%	18.0%
Adjusted profit	383.3	308.2
Minority interest	(2.4)	(1.9)
Adjusted EPS (diluted)	46.1	42.1
Dividends per share	20.45	19.30

G	rowth
_	Improving underlying growth
-	Reported growth enhanced by Penton, YPI and currency
0	perating margin
_	Benefits of higher growth, mix and synergies, offset by increased depreciation from <i>GAP</i> investments
H	igher net interest charge
_	Average debt / interest rates / FX
Iı	ncrease in effective tax rate
_	Profit mix / UK tax changes
D	ividends per share
_	6.0% growth in DPS, inline with increased GAP commitment

# STRONG FREE CASH FLOW GROWTH



#### Free Cash Flow >£400m achieved

- Underlying cash flow strong
- Benefit of Penton Information Services
- Increased Capex reflects completion of GAP Investment programme
- Tax credits from Penton and YPI offset increased US profits

#### **Operating Cash Flow / Adjusted Operating Profit =**

**91%** 

Free Cash Flow / Adjusted Operating Profit =

73%

# **ROBUST BALANCE SHEET**

#### **Robust balance sheet**


- 2.5x covenant gearing at year-end
  - Back within target range 14 months post Penton
  - Increased dividend on higher share count

#### Mix of bank debt and US PP debt

- Funding of \$500m US PP issuance in January 2017
- Funding of \$400m US PP issuance in January 2018
- US interest rate rises with c.90% debt US Dollar
- PP average coupon 4.1% and maturity over 6 years


#### **Secure Pension position**

- Defined benefit schemes closed
- Total net liabilities of £18m at year-end



#### **NET DEBT BRIDGE (£m)**

#### DEBT MATURITY AS AT 31 DEC 2017 + USPP ISSUE 4 JAN 2018 (£m)



## **ROBUST BALANCE SHEET WITH LONG-TERM FLEXIBLE FINANCING**

# **OPERATING DISCIPLINE**

#### **Portfolio Management**

#### **Academic Publishing**

- Sale of Garland
  - Reduces exposure to more volatile Lower Level textbook market

#### **Knowledge & Networking**

- Sale of majority stake in domestic conference business in Germany and Switzerland, Euroforum
  - Increased focus on Branded events in core verticals of Life Sciences, Global Finance and TMT

#### Other

 Small scale disposals in Business Intelligence and Global Exhibitions

#### 10.0% 9.2% 9.2% 8.9% 8.8% 9.0% 8.4% 8.3% 8.0% 7.0% 6.0% 2012 2015 2017 2013 2014 2016


**Return on Capital Employed (%)** 

- Full year impact of Penton addition
  - 9.9% ROCE on a cash basis in 2017, reflecting use of tax credits
- GAP investment
- Average ROCE 2012-2017 of 8.8%
- Bottom-up WACC of 7.2%

#### INVESTMENT FOR LONG-TERM GROWTH AND RETURNS


ONGOING REVIEW OF SELECTIVE NON-CORE BUSINESSES

# IMPROVING OPERATIONAL AND FINANCIAL PERFORMANCE



#### **Organic/Underlying Revenue Growth (%)\***

#### Free Cash Flow Growth (£m)




#### 2017 FULL YEAR RESULTS FEBRUARY 2018

#### **Adjusted Operating Profit Growth (£m)**



#### **Dividends Per Share Growth (p)\***



\* Revenue growth is Organic (2013-2016) / Underlying (2017); DPS figures are adjusted for impact of 2016 rights issue;

STEPHEN A. CARTER GROUP CHIEF EXECUTIVE

# GROWTH CONTINUATION

# MARKET OPPORTUNITIES

#### **MACRO THEMES**

- Global growth trends
- Monetary stimulus, interest rates and inflation
- Geo-political risk
- Power of US Tech companies
- Robotics and Artificial Intelligence
- Aging population
- Globalisation and Specialisation

#### **MARKET THEMES**

#### **B2B Events**

- Focused Scale
- Industry Specialisation

#### **Specialist Business Information**

- Focused scale
- Workflow, data and artificial intelligence

#### Scholarly Research and Reference-led Content

- Education investment and growth
- Open Access trends and opportunities

#### **REGIONAL THEMES**

#### **North America**

- Fiscal stimulus, interest rates and political debate

#### Asia

- China / Asia growth in a global context

#### **MENA**

- Oil price, growth and regional sensitivities

#### South & Latin America

- Growth, inflation and rise of the middle class

#### **UK/Europe**

Brexit ramifications

#### **VERTICAL THEMES**

#### **Health & Nutrition**

- Growth in organic, "free from" and nutritious foods

#### Life Sciences

- Biotech, genetics and drug development

#### TMT

- Internet of Things, Quantum Computing, 5G rollout

#### Agriculture

- Food demand, resource scarcity, efficiency and technology


#### **Construction & Real Estate**

- Policy stimulus, structural and cyclical growth

# **GLOBAL EXHIBITIONS: INFORMA'S LARGEST DIVISION**

#### **GROWTH TRENDS**

- Focus on major Brands in attractive verticals
- Top 30 Brands: c.£4m revenue to qualify for Top 30
- **Expand**: Effective integration of Penton and YPI
- Yield improvements: rollout of Customer Value Initiative
- Product innovation: Medlab and Arab Health
- Partnerships: Extension of agreement with Monaco for US shows
- Market Maker strategy: rollout of vertical-specific web platforms



#### **REVENUE BY REGION**



c.200

Brands



**£530m** 2017 revenue

Exhibition space

2.2m+

Visitors

1,400+

Colleagues

>60% Top 30 Exhibitions % of revenue

## CONTINUED STRONG GROWTH OPPORTUNITIES

# MARKET MAKER STRATEGY



Target attractive industry verticals: B2B, fragmented, growing, international, high value and high margin product

Build depth in verticals through multiple brands, across the supply chain


Expand internationally to create focused scale in verticals

Develop capabilities in data, digital and marketing solutions: collect and manage customer data, buyer/seller knowledge and market intelligence


Organise around customers and verticals ahead of products and geographies

From exhibition organiser to Market Maker: incremental growth from depth of market knowledge and more strategic customer relationships, offering range of face-to-face, information and lead generation products

# MARKIT MAKR PRODUCT: OMNIA IN LIFE SCIENCES



# MARKIT MAKR PRODUCT: PROGRESSIVE ROLLOUT ACROSS VERTICALS





# **BUSINESS INTELLIGENCE: IMPROVING PERFORMANCE**

#### **GROWTH TRENDS**

- Subscription-led business with c.90% renewal rates
- Momentum in other revenues following relaunch of **Consulting...**
- ...and launch of Marketing Services as Informa Engage
- Major rollout of new products & enhanced platforms following GAP Investment Programme...
- ...including new platforms at EPFR Global, Lloyd's List and Citeline
- Customer Engagement Programme and Key Accounts
- Focus on new business pipeline and lead conversion

#### **REVENUE BY REGION**





### INVESTMENT AND CAPABILITY DRIVING GROWTH

# **BUSINESS INTELLIGENCE PRODUCT AND PLATFORM LAUNCHES**



			nforma 👻				
Citeline 🔊	Trialtrove	Sitetrove	Back to the legacy Trialtrove, Sitetrove   Soved Sev	inches   Help 🗸	Log out As	k the Analy	*
Investigators T Enter	a single term to lookup	investigators by name, specialty	disease, etc.				
< Investigeter - Full Name Investigeter ID	404,923 investig	ators Viewrelated: Trials   In	vestigators   Organizations Column counts   50	esuits 🗸 Showl	Hide columns 🗸	Table I	Map
Specialty	<						2
Investigator Notes	fullNess	Specialities 	Organization Name	Country	Orgoing Trials	Crigolog Hatching	
Location - Investigator Region	't Jong, Geert W	Clinical Pharmacology, Pediatrics - G enerol	The Children's Hospital Foundation - Children's Hospital Research Institute of Monitobs (The Manitobo Institute of Child Health (HIGH)	Conoda	0	0	
Investigator Country	't Lom-Boer, Jorine	Surgery - General	Radboud Universiteit - Radboud Universiteir Medisch Ce ntrum (Radboudumc)	Netherlands	1	1	
Investigator State	-, Wulijbate'er	Rheumotology	Inner Hongolia University for Nationalities - Affiliated H aspital	Chine	1	1	
Investigator Post Code Investigator Rodius	A't Hert, Nils	(NIR)/Other	Isolo Ziekenhuis (Isolo Klinieken) - Zwolle (Isolo Kliniek en - Lacotle Sophia)	Netherlands	0	0	
	Annalas Alberta	August Paker	Restanted at the sector of Multiple Palances (MMUL). By	Advantis Data atta of \$	Feedback		-

#### **New Citeline platform**

- Intelligence, data and analysis on completed/ongoing clinical trials
- 40,000 data sources, 265k clinical trials and 400k investigators
- Enhanced capabilities, flexibility, APIs

Financial intelligence





#### **New EPFR platform**

- No 1 provider of fund flow and asset allocation data
- Scalable research and analytics site
- Data visualisation, investment signals, APIs, analytical/insight tools

# **BUSINESS INTELLIGENCE PRODUCT AND PLATFORM LAUNCHES**

# Agribusiness intelligence



#### **New IEG Vu platform**

- Critical supply, demand, price and trade data, as well as proprietary forecasts for crops and livestock commodities
- Digital platform with search tools, data visualisation, APIs, flexible analytical tools etc





#### **New Ovum Forecaster product**

- Combined forecasting on broadband, cellular, TV services and technologies
- Covering more than 2,500 services, covering 1,000 metrics across 220 markets




# ACADEMIC PUBLISHING: CONSISTENT STRENGTH

#### **GROWTH TRENDS**

- Upper Level scholarly research and specialist, reference-led content
- High renewal rate and consistent growth in Journals
- Improved Books performance through operational fitness programme
- Reduced exposure to Lower Level textbooks following sale of Garland
- Investment in content discoverability, analytics and author services
- Investment in Academic Digital Services through Colwiz
- Expansion of Open Access capability and capacity through Dove

#### **REVENUE BY REGION**





## **RESILIENT GROWTH AND STRONG CASHFLOW**

# ACADEMIC PUBLISHING PRODUCT INVESTMENT

#### **Enhanced Books Platform**

- Unified platform for all books content
- Increased flexibility and discoverability of content
- c.140k titles covered
- >2,000 customers migrated onto platform with
  >500k sessions to date
- www.taylorfrancis.com "Artificial Intelligence"



	icis												
My Wo	ork								Submit N	lew Manu	script	L	
Submission 172449672				Journa Dix-N		Si	atus ubmission in rogress	Updated 30 Nov 17		Resume Delete		L	
Submission 171827387				Journ: Coge	រl nt Enginee		atus nder review	Updated 30 Nov 17				L	
Submission 179365435	Title Collaborate on CP	DASHBO	ARD	Journ	il et Educatio		atus ubmission in	Updated 20 More 17		Resume		e	•
	Welcome Julie Sutton	«							QUERIES				
	DASHBOARD	ACTION	INED QUERIES	~	ECROM	ACC REAL	N. RAISED BY		dorwer				
	MY QUERIES		ED QUERIES								174		
	2 MY DRAFT	ACTION	SUBJECT	ACRONOM	DATE OF LAST	DMAIL	SINDER	STATUS					
	ALL JOURNALS	*	Multi email test	1515	16-10-2017		Julie Sution@tandf.cs.uk	(10.44.87) F		0	<u> </u>	4	
		OVERDU	OVERIES						0140.0	0.61016	ESC-L-TE	0PEN	
	REPORTS	ACTION	SUBJECT	ACTONYM	DATE OF	LASTEMAL	SENDER	STATUS	MY NOTES				
	🔅 settings 🔷 '	UNREAD	QUERIES					ViewAll					
	(Ť) HELP	ACTION	SUBJECT		ACRONOM	DATE OF LAST END	al. SINDER	STATUS					
					UE58	04-12-2017	verkateshrg@codemantra.in	(CA14)					

#### **Author Services**

- Journals communications hub for managing queries and reports
- Research dashboard for article approvals and OA funding
- Researcher portal for submitting and managing manuscripts
- Data and analytics

# ACADEMIC PUBLISHING INVESTMENT

#### **Dove Medical Press**

- Large, independent OA publisher
- Increases OA portfolio to 200+ journals
- Quality range of titles in Health Sciences, many indexed with growing impact factors
- OncoTargets and Therapy, International Journal of Nanomedicine
- Strengthened OA capacity and capability



#### Colwiz

- wisdom.ai, the world's largest research knowledge graph
- Powerful research tool that helps collate, track and analyse subjects and themes
- Covering 90m publications, 50m authors and 4.2bn facts to date
- Machine learning algorithms





# KNOWLEDGE & NETWORKING: FOCUS, SIMPLIFY AND GROW

#### **GROWTH TRENDS**

- Increased portfolio focus: Germany, Switzerland, Brazil
- Focus on end markets: TMT, Life Sciences, Global Finance
- Develop community Brands
- Maximise Networking and Partnering opportunities
- Digital community engagement, content and revenue
- Cross-divisional opportunities and Marketing Services
- Non-renewal of managed event contract

#### **REVENUE BY REGION**





**c.1,000** 

40+

Events with £1m+ revenue

c.£100m

1,000+

Colleagues

Annual revenue from SPEX

# STREAMLINED PORTFOLIO ORGANISED AROUND CORE VERTICALS

£283m


2017 Revenue


150k+

Delegates


# KNOWLEDGE & NETWORKING: FOCUS, SIMPLIFY AND GROW

- Focus on branded events in core verticals of Life Sciences, Global Finance and TMT
- Targeted exit from regional domestic conference businesses:
  - Spain
  - Portugal
  - South Africa
  - Netherlands Amsterdam
  - Netherlands Eindhoven
  - Sweden
  - Denmark
  - Russia
  - Brazil
  - Germany & Switzerland





# INFORMA GROUP: QUALITY AND VISIBILITY OF EARNINGS



# **2018: GROWTH CONTINUATION**

#### **POST-GAP FINANCIAL FRAMEWORK**

GLOBAL EXHIBITIONS

revenue growth

#### ACADEMIC PUBLISHING

Consistent underlying revenue growth

## BUSINESS INTELLIGENCE

3%+ underlying revenue growth

# KNOWLEDGE & NETWORKING

Positive underlying revenue growth

# **2018 GROWTH CONTINUATION**



# **RECOMMENDED OFFER FOR UBM**


- Recommended offer for UBM to create a leading B2B Information Services Group
- For every UBM share
  - 1.083 New Informa Shares and 163p in cash
- Highly complementary portfolios
- Operating momentum following *GAP* and *Events First* programmes
- Operating Scale and Industry Specialisation
  - •At least £60m of cost savings

•Revenue opportunities in cross-marketing, internationalisation, sponsorship, digital & data

 Attractive earnings accretion in first full year, ROIC ahead of WACC within 3 full years

Expected Offer Timetable					
30 January	Publication of Offer Announcement				
28 February	Informa and UBM 2017 Full Year Results				
14 March	Publication of Circular, Prospectus and Scheme Document				
17 April	Shareholder meetings and vote				
20 April	Record date for final dividends				
Q2 2018	Anticipated completion date in Q2 2018				

# 2017: GROWTH ACCELERATION PLAN COMPLETED



The goal is simple but demanding: progressively to return every part of our business to growth, and simultaneously to build the capabilities and platforms needed for future scale and consistent performance.

**Informa Annual Report** 2014

# **APPENDICES**

# **KEY INDUSTRY VERTICALS**



# BALANCE SHEET SUMMARY

		2017 £m		2016 £m
Intangibles and goodwill		 4,309.6		4,501.6
Fixed assets		31.8		24.1
Other non-current assets		15.2		16.6
Current assets		480.6	=	439.7
Deferred income		(534.6)		(563.0)
Other current liabilities		(352.8)		(311.1)
Net debt		(1,373.1)		(1,485.4)
Other non-current liabilities		(346.0)		(434.7)
Net Assets	347	2,230.7	1	2,187.8

# TAX SUMMARY

	2017	Tax	ETR
	£m	£m	%
Reported Profit Before Tax	268.8	44.9	(16.7%)
Adjusted for:			
Intangible asset amortisation	157.8	(58.6)	
Deferred tax (charge)/credit arising from revised treatment of certain non-UK intangible assets	-	3.1	
Benefit of US goodwill amortisation for tax purposes only	- 8	12.7	
Impairment	5.6		
Redundancy and reorganisation costs	12.9	(3.8)	
Acquisition and integration costs	24.0	(9.3)	
Subsequent re-measurement of contingent consideration	(0.1)	State .	
Loss/(profit) on disposal of businesses	17.4	(6.3)	
Deferred tax credit on intangible assets arising from UK corporation tax rate change	-	(0.4)	
Adjusted profit and tax on adjusting items	486.4	(17.7)	
Tax adjusting item for US federal tax reform	- 2	(85.4)	
Adjusted Profit before Tax	486.4	(103.1)	21.2%

# OPERATING CASH FLOW SUMMARY

	2017 £m		2016 £m
Adjusted operating profit	 545.5		415.6
Depreciation of property and equipment	9.2		6.5
Software and product development amortisation	24.8		14.2
Share-based payments	5.4	1.1	3.9
Adjusted share of joint venture and associate results			(0.8)
Loss on disposal of other assets			0.1
Adjusted EBITDA	584.9	1	439.5
Net capital expenditure	(79.0)	1.1.1	(52.0)
Working capital movement	(11.1)		6.3
Operating cash flow	494.8		393.8
Adjusted cash conversion	91%	ALC: NO	95%
Restructuring and reorganisation	(8.6)		(9.8)
Net interest	(51.8)		(35.0)
Taxation	(33.5)	1	(43.3)
Free cash flow	400.9		305.7

# OTHER ADJUSTING ITEMS

		2017 £m			2016 £m
Intangible asset amortisation	1.10	157.8			116.4
Impairment		5.6			67.7
Restructuring and reorganisation		12.9			7.2
Acquisition and integration		24.0	1.1.1		33.1
Subsequent re-measurement of contingent consideration		(0.1)		-	(7.4)
Adjusting items in operating profit		200.2	1 3 4 1 4 3 A	1.32	217.0
Loss on disposal		(17.4)			(39.8)
Investment income		-			58.9
Adjusting items in profit before tax		217.6		18.910	197.9

# CURRENCY SENSITIVITY

Major Currencies	Average Rates		<b>Closing Rates</b>	
	2017	2016	2017	2016
USD	1.29	1.36	1.35	1.23
			1.	
Impact of a 1 cent movement in 2017:				
	USD			
Revenue	£8.5m			
Adjusted Operating Profit	£3.5m			
Adjusted Diluted Earnings Per Share	0.30p			

# SPONSORED ADR PROGRAMME

#### Informa ADRs trade on the US over-the-counter (OTC) market

Symbol	IFJPY
ISIN	US45672B305
Ratio	1 ADR : 2 ORD
Effective date	1 <sup>st</sup> July 2013
Underlying ISIN	JE00B3WJHK45
Depositary Bank	BNY Mellon

#### For any questions relating to Informa ADRs, please contact BNY Mellon

Damon Rowan

Tel: +44 20 7163 7511

E-mail: damon.rowan@bnymellon.com